El interés en corto de EyePoint Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de EyePoint Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

EyePoint Pharmaceuticals (NASDAQ:EYPT) Bolsa, Informe de interés en corto

EYEPOINT PHARMACEUTICALS INC

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals Inc

Barclays analyst Theresa Chen maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Equal-Weight and raises the price target from $106 to $115.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Phillips 66, Raises Price Target to $115

ORIX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IX#NYSE">IX</a>) reported quarterly earnings of $0.46 per share. This is a 37.84 percent decrease over earnings of $0.74 per share from the same period last year. The company reported $4.72 billion in sales this quarter. This is a 9.75 percent decrease over sales of $5.23 billion the same period last year.

Earnings

ORIX Q4 EPS $0.46 Down From $0.74 YoY, Sales $4.72B Down From $5.23B YoY

Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 75.57 percent increase over losses of $(1.31) per share from the same period last year.

Earnings Beats

BBLG

Bone Biologics Q1 EPS $(0.32) Beats $(0.48) Estimate

Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) reported $85.17 million in sales this quarter. This is a 69.57 percent increase over sales of $50.23 million the same period last year.

Morgan Stanley Market Vectors Rupee/USD ETN

Infinity Natural Q1 Sales $85.17M Up From $50.23M YoY

Barclays analyst Theresa Chen maintains MPLX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLX#NYSE">MPLX</a>) with a Overweight and lowers the price target from $55 to $52.

MPLX

Barclays Maintains Overweight on MPLX, Lowers Price Target to $52

Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.41) by 36.59 percent. This is a 92.95 percent increase over losses of $(3.69) per share from the same period last year.

GNPX

Genprex Q1 EPS $(0.26) Beats $(0.41) Estimate

Barclays analyst Lauren Lieberman maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Equal-Weight and lowers the price target from $60 to $57.

Barclays Maintains Equal-Weight on Molson Coors Beverage, Lowers Price Target to $57

Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.70) by 32.86 percent. This is a 89.76 percent increase over losses of $(4.59) per share from the same period last year.

PALI

Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Getty Images Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) reported first-quarter financial results Monday after the close. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/05/g45359438/getty-images-reports-first-quarter-2025-results">from the print</a>.
Q1 Earnings: Getty Images reported first-quarter revenue of $224.08 million, missing analyst <a href="http://benzinga.com/quote/gety/estimates">estimates</a> of $236.01 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported a first-quarter adjusted loss of 14 cents per share.
Total revenue was up 0.8% year-over-year and annual subscription revenue climbed 5.4% year-over-year. Here&#8217;s a breakdown of revenue by category:
<ul class="wp-block-list">
<li>Creative revenue: $132.3 million, down 4.8%</li>
</ul>
<ul class="wp-block-list">
<li>Editorial revenue: $82.6 million, up 4% </li>
</ul>
Getty Images generated cash flow from operations of $15.4 million and reported negative free cash flow of $300,000. The company ended the quarter with $114.6 million in cash.
&#8220;Results in the&nbsp;first quarter&nbsp;were consistent with our expectations, with growth highlighted by gains across our subscription business, and continued customer value delivered through our offerings,&#8221; said Craig Peters, CEO of Getty Images. 
&#8220;We remain committed to investing in the core assets of our company and continuing to evolve our offering in ways that deepen our relevance for our customers. We believe this strategy positions us well to achieve our 2025 outlook and beyond.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">NuScale Power Reports Q1 Results: Details</a>
Guidance: Getty raised its full-year 2025 revenue guidance from a range of $918 million to $955 million to a new range of $931 million to $968 million. Analysts are forecasting full-year revenue of $942.67 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Getty Images noted that it continues to work cooperatively with the U.S. Department of Justice and other non-U.S. regulators to obtain regulatory clearance for its proposed merger with Shutterstock.
GETY Price Action: <a href="http://benzinga.com/quote/gety">Getty Images shares</a> were down 1.99% in after-hours, trading at $1.97 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/brodogg1313">Eric Broder Van Dyke</a>/Shutterstock.

Guidance

After-Hours Center

Movers

Media

GETY

Getty Images Reports Q1 Results Below Estimates, Raises FY25 Guidance, Shares Slide

SK Telecom Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKM#NYSE">SKM</a>) reported quarterly earnings of $0.65 per share. This is a 4.41 percent decrease over earnings of $0.68 per share from the same period last year. The company reported $3.07 billion in sales this quarter. This is a 8.80 percent decrease over sales of $3.37 billion the same period last year.

SK Telecom Co Q1 EPS $0.65 Down From $0.68 YoY, Sales $3.07B Down From $3.37B YoY

eXoZymes Inc. - Common Stock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) reported quarterly losses of $(0.22) per share. This is a 37.5 percent decrease over losses of $(0.16) per share from the same period last year.

EXOZ

eXoZymes Inc. - Common Stock Q4 EPS $(0.22) Down From $(0.16) YoY

Management

PROV

Provident Financial Holdings Appoints Peter C. Fan As  Chief Financial Officer, Effective May 12, 2025

Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) reported quarterly earnings of $0.01 per share. This is a 105.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported $135.00 thousand in sales this quarter. This is a 33.52 percent decrease over sales of $203.06 thousand the same period last year.

OMEX

Odyssey Marine Explr Q1 EPS $0.01 Up From $(0.18) YoY, Sales $135.00K Down From $203.06K YoY

Barclays analyst Ramsey El-Assal maintains Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) with a Equal-Weight and raises the price target from $4 to $5.

Barclays Maintains Equal-Weight on Marqeta, Raises Price Target to $5

Paramount Gold Nevada (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PZG#AMEX">PZG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year.

Earnings Misses

Paramount Gold Nevada Q3 GAAP EPS $(0.04) Misses $(0.02) Estimate

Biohaven (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(1.49) by 10.07 percent. This is a 7.34 percent increase over losses of $(1.77) per share from the same period last year.

BHVN

Biohaven Q1 Adj. EPS $(1.64) Misses $(1.49) Estimate

Barclays analyst Theresa Chen maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Overweight and raises the price target from $141 to $159.

Barclays Maintains Overweight on Marathon Petroleum, Raises Price Target to $159

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 10 years by 7.47% on an annualized basis producing an average annual return of 18.06%. Currently, Sprouts Farmers Market has a market capitalization of $15.34 billion. 
Buying $100 In SFM: If an investor had bought $100 of SFM stock 10 years ago, it would be worth $522.60 today based on a price of $156.71 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747085424_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Barclays analyst Ramsey El-Assal maintains MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Equal-Weight and raises the price target from $14 to $16.

MARA

Barclays Maintains Equal-Weight on MARA Holdings, Raises Price Target to $16

WIIM

COIN

Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective before the opening of trading on Monday, May 19.

Comments

EyePoint Pharmaceuticals

Interés en corto

EyePoint Pharmaceuticals (NASDAQ:EYPT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL